In November 2024, a regulatory advisory board said the benefits of Zynquista does not outweigh the risks in adults with type ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback